Business Context and Reporting Period
This Form 8-K Current Report was filed by Curanex Pharmaceuticals Inc on March 6, 2026, covering events occurring on March 1, 2026. The company, incorporated in Nevada and trading on the Nasdaq Capital Market under the symbol CURX, is classified as an emerging growth company. The filing primarily addresses the entry into material definitive employment agreements with its Chief Executive Officer and Chief Operating Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms and employment conditions.
Material Changes and Executive Agreements
On March 2, 2026, the Company entered into new executive employment agreements effective March 1, 2026, for its top leadership:
- CEO Agreement (Jun Liu):
- Role: Chief Executive Officer and President.
- Term: Four years from the effective date, renewable for successive one-year periods upon mutual consent.
- Compensation: Annual base salary of $393,600.
- Benefits: Eligibility for equity incentive plans, standard employee benefits, and reimbursement of business expenses.
- Perks: Company coverage of monthly automobile lease expenses totaling $3,998.
- Termination Provisions: In the event of termination without cause or resignation for "good reason" (e.g., material reduction in salary or duties), the executive receives three months of base salary, continued benefits, and immediate vesting of all unvested options or restricted shares.
- COO Agreement (Dr. Liqin Xie):
- Role: Chief Operating Officer.
- Term: Employment at will, terminable by either party at any time with or without cause.
- Compensation: Annual base salary of $180,000.
- Benefits: Eligibility for equity incentive plans and standard employee benefits.
- Termination Provisions: In the event of termination without cause, the executive receives three months of base salary, continued benefits, and immediate vesting of all unvested options or restricted shares.
Both agreements include restrictive covenants regarding non-competition, non-disclosure, and non-solicitation, and require the assignment of inventions to the Company.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding the company's business strategy or market conditions. The primary risk disclosed relates to the financial obligations associated with the new executive compensation packages and the potential for accelerated vesting of equity awards upon specific termination events.
Investor Verification Checklist
- Verify the total annual cash compensation commitment for the CEO and COO ($573,600 combined base salary).
- Review the attached Exhibits 10.1 and 10.2 for the full text of the employment agreements and specific definitions of "cause" and "good reason."
- Assess the potential dilution impact if unvested options or restricted shares are accelerated due to termination without cause.
- Confirm the status of the Company's equity incentive plan mentioned in the agreements, as it is noted as "to be adopted."
- Monitor future filings for the adoption of the equity incentive plan and any subsequent grants to these executives.